Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
Cancer Invest ; 40(4): 337-347, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-35100066

RESUMO

We detected PD-L1 and intra-tumoral CD8+ T lymphocytes (CD8+ TIL) in 19 patients with esophageal carcinosarcoma (ECS). The median follow-up period of these patients was 43 months, and the three- and five-year survival rates were 78.9 and 63.2%, respectively. No statistically significant correlation was observed between PD-L1 and CD8+ TIL in sarcomatous components(SC) (r = -0.262, p = 0.279) and epithelial carcinomatous (EC) (r = 0.055, p = 0.824). This study examined the immunological markers in ECS for the first time. PD-L1 is highly expressed in the SC and is associated with a poorer prognosis.


Assuntos
Carcinossarcoma , Neoplasias Esofágicas , Antígeno B7-H1/metabolismo , Linfócitos T CD8-Positivos , Carcinossarcoma/metabolismo , Neoplasias Esofágicas/metabolismo , Humanos , Linfócitos do Interstício Tumoral/metabolismo , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...